Identification of a tumor suppressor gene of malignant mesothelioma and functional analysis of the NF2 and p16 genes
| Project/Area Number |
12670556
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
SEKIDO Yoshitaka University Hospital, Nagoya University, Assistant Professor, 医学部・附属病院, 講師 (00311712)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOKOI Toyoharu School of Medicine, Nagoya University, Professor, 医学部, 教授 (40200886)
SHIMOKATA Kaoru University Hospital, Nagoya University, Professor, 医学部・附属病院, 教授 (10022906)
|
|---|
| Project Period (FY) |
2000 – 2001
|
| Project Status |
Completed (Fiscal Year 2001)
|
| Budget Amount *help |
¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2001: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Keywords | Malignant mesothelioma / lung cancer / chromosome 3p / homozygous deletion / positional cloning / tumor suppressor gene / cell line / β-catenin遺伝子 / 染色体3p21.3 / 点突然変異 / クローニング |
|---|
| Research Abstract |
To isolate a new tumor suppressor gene of human malignant mesothelioma, we searched for the abnormalities of chromosome 3p showing frequent loss of heterozygosity and identified that the β-catenin gene (CTNNB1), located at 3p21.33, is homozygously deleted in a malignant mesothelioma cell line, NCI-H28. We constructed a genomic DNA library from NCI-H28, and identified that the breakpoint of the homozygous region was located in intron 1 of β-catenin, which was rearranged to another region located at 3p21, rbc. We further cloned a new gene (MTSK1) of 4153 bp from this region and found that this putative protein product contains a kinase motif at the amino terminal. Northern blot analysis demonstrated that its message sizes are 4.7 and 2.1 kb and that MTSK1 is expressed in the testis at a high level but at low levels in other tissues. We studied for the mutation in 9 malignant mesotheliomas and 68 lung cancers by PCR-SSCP analysis and identified several aberrant mobility shifts, which are now being characterized by sequencing. A protein analysis is also scheduled in the future with antibodies that are under synthesis against MTSK1. Meanwhile, we established new malignant mesothelioma cell lines, Y-Meso8A and Y-Meso8B, from a patient and tested tumorigenecity of these cell lines by transplantation in nude mice. Mutational analysis for tumor suppressor genes (NF2, p16, p53, E-cadherin) and oncogene (KRAS, NRAS, and MDM2) showed that these cell lines do not harbor either mutations of these genes.
|
Report
(3 results)
Research Products
(3 results)
